Phase II study of celecoxib, irinotecan, and capecitabine in patients with advanced colorectal cancer

被引：0
|
作者：
El-Rayes B
Shields, A.
Zalupski, M.
Bekaii-Saab, T.
Heilbrun, L.
Vaishampayan, U.
Manza, S.
机构：
[1] Karmanos Canc Ctr, Dearborn, MI USA
[2] Univ Michigan, Detroit, MI USA
[3] Ohio State Univ, Columbus, OH 43210 USA
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [31] A phase II trial of Capecitabine (X) and Irinotecan (I) in a biweekly schedule in patients with untreated advanced colorectal cancer (ACRC)
    Garcia-Alfonso, P.
    Perez MAnga, G.
    Gonzalez, M. C.
    Lopez, P.
    Gonzalez, E.
    Belon, J.
    Molina, M.
    Pachon, V.
    Iglesias, L.
    Siso, I.
    EJC SUPPLEMENTS, 2005, 3 (02): : 181 - 181
  • [32] A pilot phase II study of capecitabine in advanced or recurrent colorectal cancer
    Kondo, Y
    Terashima, M
    Sato, A
    Taguchi, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (04) : 195 - 201
  • [33] A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer
    Rea, DW
    Nortier, JWR
    Huinink, WWT
    Falk, S
    Riche, DJ
    Maughan, T
    Groenewegen, G
    Smit, JM
    Steven, N
    Bakker, JM
    Semiond, D
    Kerr, DJ
    Punt, CJA
    ANNALS OF ONCOLOGY, 2005, 16 (07) : 1123 - 1132
  • [34] Pharmacokinetics and metabolism of irinotecan combined with capecitabine in patients with advanced colorectal cancer
    Czejka, M
    Schueller, J
    Hauer, K
    Ostermann, E
    ANTICANCER RESEARCH, 2005, 25 (04) : 2985 - 2990
  • [35] A Phase II Study of Irinotecan and Capecitabine for Patients with Unresectable Liver-only Metastases from Colorectal Cancer
    Zhao, Ren
    Zhu, Jianwei
    Ji, Xiaopin
    Cai, Jianhua
    Wan, Fangjun
    Li, Qing
    Zhong, Baoliang
    Tucker, Steven
    Wang, Daoyuan
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (01) : 10 - 16
  • [36] PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF IRINOTECAN, CAPECITABINE AND BEVACIZUMAB IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Garcia Alfonso, Pilar
    Chaves, Manuel
    Munoz, Andres
    Salud, Antonieta
    Garcia-Giron, Carlos
    Gravalos, Cristina
    Massuti, Bartomeu
    Gonzalez-Flores, Encarnacion
    Queralt, Bernardo
    Lopez-Ladron, Amelia
    Losa, Ferran
    Oltra, Amparo
    Jose Gomez, Ma
    Manuel Campos, J.
    Aranda, Enrique
    ANNALS OF ONCOLOGY, 2012, 23 : 103 - 104
  • [37] Open label phase II study of capecitabine in combination with irinotecan (XEPTO) in patients with metastatic colorectal Cancer (MCRC)
    Raafat, Jahangir
    Sadighi, S.
    Shahrasbi, A. A.
    ANNALS OF ONCOLOGY, 2004, 15 : 87 - 87
  • [38] Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in metastatic colorectal cancer (mCRC) patients
    Garcia Alfonso, Pilar
    Chaves-Conde, Manuel
    Munoz, Andres
    Salud, Antonia
    Garcia-Giron, Carlos
    Gravalos Castro, Cristina
    Massuti, Bartomeu
    Gonzalez Flores, Encarnacion
    Queralt, Bernardo
    Lopez Ladron, Amelia
    Losa, Ferran
    Oltra Ferrando, Amparo
    Gomez Reina, Maria Jose
    Garcia-Carbonero, Rocio
    Garcia-Escobar, Ignacio
    Aranda, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [39] Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in patients with metastatic colorectal cancer (mCRC)
    Garcia Alfonso, P.
    Chaves, M.
    Munoz Martin, A.
    Salud Salvia, A.
    Vilchez, R.
    Yuste, A.
    Gravalos Castro, C.
    Queralt Merino, B.
    Gonzalez Flores, E.
    Lopez Ladron, A.
    Losa, F.
    Oltra Ferrando, A.
    Gomez Reina, M. J.
    Campos, J. M.
    Aranda, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Capecitabine (X) and Irinotecan (I), in a biweekly schedule, for patients (Pts) with advanced/metastasic colorectal cancer (MCRC): interim analysis of a phase II study
    Garcia-Alfonso, Pilar
    Gonzalez, M. C.
    Gonzalez, E.
    Molina, M.
    Monoz, A.
    Abad, G.
    Garcia, S.
    Lopez, P.
    Belon, J.
    Perez-Manga, G.
    ANNALS OF ONCOLOGY, 2004, 15 : 89 - 89
12345